United Therapeutics Corporation NMS · UTHR
Price alert —
Sign in to get a one-time email the moment UTHR crosses your price. Free accounts included.
Sign in / create a free accountUnited Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR last traded at $535.67, up 1.2% on the day; that's in the middle part of its 52-week range ($455.63–$609.35). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.
The next scheduled earnings report (2026-07-29) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 lower, -0.53 ATR from EMA21 — no notable pattern
- · KC1 lower stretch — light dip
- · RSI hook from oversold (44)
- · Stochastic bull cross in oversold
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 44), the trend is quiet (ADX 18), and volume is about normal (0.8×). On the business side, revenue is shrinking 2% year over year and the business keeps about 18 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $209.54 (fair range $210–$489); today's price sits 154% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 4.47 (antifragile)
- ✓ Current ratio 6.60 (antifragile)
- ✓ Debt/equity 0.11 (antifragile)
- ⚠ Receivables growing faster than revenue
- ⚠ Inventory growing faster than revenue
Price implies ~17% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
UTHR is a $22.7 billion company, priced at 20× last year's earnings, and it moves more calmly than the market (beta 0.6).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-06
- EPS (act / est)
- 5.82 / 6.86
- Surprise
- -15.1%
- Next report
- 2026-07-29
About
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remod…